The importance of IL-1 and IL-6 in the pathogenesis of s-JIA and AOSD was proven by the dramatic effects of IL-1 inhibitors (anakinra, rilonacept, and canakinumab) and IL-6 inhibitors (tocilizumab [TCZ], sarilumab) in patients with s-JIA and AOSD (58–62). Here, IL6 is linked to juvenile idiopathic arthritis.